Gossamer Bio (GOSS) Stock Price, News & Analysis

Company Overview

Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing medicines for diseases with significant unmet medical needs. The company concentrates primarily on immunology, inflammation and pulmonary disorders.

Its lead product candidate is seralutinib, an inhaled tyrosine kinase inhibitor designed to target pathways involving platelet-derived growth factor, colony-stimulating factor 1 and stem cell factor receptors. Gossamer is developing seralutinib for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. The company has also pursued additional investigational programs in immunology and inflammatory diseases.

Gossamer Bio was founded in 2015 and is headquartered in San Diego, California. Its programs are advanced through clinical development and collaborations intended to support development and potential commercialization in the United States and international markets. The company’s leadership includes Chief Executive Officer Faheem Guirgis.

Key Stats

• Today's Range: $10.60 to $12.15
• 50-Day Range: $8.43 to $14.39
• 52-Week Range: $8.29 to $309.60
• Volume: 188,926 shs
• Average Volume: 176,783 shs
• Market Capitalization: $68.79 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $246.40
• Consensus Rating: Hold

Gossamer Bio Stock Analysis - MarketRank™

Gossamer Bio scored higher than 56% of companies evaluated by MarketBeat, and ranked 447th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Hold

Consensus Rating

Gossamer Bio has received a consensus rating of Hold. The company's average rating score is 2.30, and is based on no strong buy ratings, 5 buy ratings, 3 hold ratings, and 2 sell ratings.

Upside Potential

Gossamer Bio has a consensus price target of $246.40, representing about 2,092.2% upside from its current price of $11.24.

Amount of Analyst Coverage

Gossamer Bio has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Gossamer Bio are expected to grow in the coming year, from ($33.00) to ($15.12) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Gossamer Bio is -0.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Gossamer Bio is -0.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

22.87% of the float of Gossamer Bio has been sold short.

Short Interest Ratio / Days to Cover

Gossamer Bio has a short interest ratio ("days to cover") of 7.52.

Change versus previous month

Short interest in Gossamer Bio has recently decreased by 6.75%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Gossamer Bio does not currently pay a dividend.

Dividend Growth

Gossamer Bio does not have a long track record of dividend growth.

News and Social Media

• Score: 1.8 / 5
• News Sentiment: -0.18

News Sentiment

Gossamer Bio has a news sentiment score of -0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Gossamer Bio this week, compared to 8 articles on an average week.

Search Interest

Only 4 people have searched for GOSS on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.

MarketBeat Follows

4 people have added Gossamer Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Gossamer Bio insiders have not sold or bought any company stock.

Percentage Held by Insiders

4.15% of the stock of Gossamer Bio is held by insiders.

Percentage Held by Institutions

81.23% of the stock of Gossamer Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 11/10/2026
• Today: 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:GOSS
• CIK: 1728117
• Web: www.gossamerbio.com
• Phone: (858) 684-1300
• Fax: N/A
• Employees: 162
• Year Founded: 2015

Price Target and Rating

• Average Price Target for Gossamer Bio: $246.40
• High Price Target: $720.00
• Low Price Target: $32.00
• Potential Upside/Downside: +2,092.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.30
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($56.00)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$170.37 million
• Net Margins: -159.49%
• Pretax Margin: -159.60%
• Return on Equity: N/A
• Return on Assets: -112.10%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.60
• Quick Ratio: 0.53

Sales & Book Value

• Annual Sales: $48.47 million
• Price / Sales: 1.42
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($20.08) per share
• Price / Book: -0.56

Miscellaneous

• Outstanding Shares: 6,120,000
• Free Float: 5,857,000
• Market Cap: $68.79 million
• Optionable: Optionable
• Beta: 2.28